Nephrotoxic effects of cadmium exposure are well established in humans and experimental animals. An early manifestation of such toxicity is calciuria a few hours after injection of CdMT in rats. Protection against calciuria and other adverse effects such as proteinuria (occurring later) is offered by pretreatment with Cd, which effectively induces metallothionein synthesis. In the present experiment, one group of animals was given pretreatment with CdCI2 to induce metallothionein synthesis. The comparison group was left without pretreatment. The distribution of Cd from a normally nephrotoxic dose of 109CdMT was studied by gel chromatography in subcellular fractions of kidney cortex in both groups. In the pretreated animals, 109Cd in the plasma membrane and microsome fractions of renal cortical cells was mainly bound to metallothionein and other low molecular weight proteins at 4 hr. In nonpretreated animals the major part of 109Cd was bound to high molecular weight proteins. These findings indicate that membrane proteins may be important targets for Cd when inducing nephrotoxicity and that sequestering of Cd by metallothionein (and other low molecular weight proteins) may be a mechanism of protection. -Environ Health Perspect 102 (Suppl 3):191-194 (1994) 
Introduction
Renal tubular dysfunction may develop in experimental animals and in humans as a result of long-term exposure to Cd (1) . After absorption via pulmonary or gastrointestinal routes, Cd is transported in plasma initially bound to albumin and other larger proteins (2) . Cadmium-albumin is taken up predominantly by the liver and Cd is released from albumin in this organ. The released Cd induces synthesis of metallothionein in liver; and some time after uptake in the liver, most Cd is bound to metallothionein (3) . A small proportion of metallothionein-bound Cd will be released into plasma, and because of its low molecular weight, it will be efficiently transported through the glomerular membrane and will reach the tubular fluid in the kidney. It will be further taken up 
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the proximal tubule and transported into lysosomes where metallothionein is split from Cd (4) (5) (6) . The released Cd is believed to constitute the toxic principle in cell. The rate at which such Cd is bound to newly synthesized metallothionein in renal cells is believed to be a key factor in determining whether or not renal tubular damage occurs (7) (8) (9) . Pretreatment with CdCl2, which effectively induces the synthesis of metallothionein in renal cells, prevented acute nephrotoxicity from normally occurring after an injected challenge dose (0.4 mg/kg) of Cd-metallothionein (10) . These observations gave general support to the idea that intracellular metallothionein can prevent toxicity by sequestering Cd from sensitive targets. However, it has not previously been demonstrated which cellular components are the critical targets for Cd in the renal cells, and it has thus been difficult to demonstrate the role of metallothioneinbound and nonmetallothionein-bound Cd in relation to development of renal damage. In recent studies (11, 12) , it was shown that an increased urinary Ca excretion is an early manifestation of Cd nephrotoxicity in the Cd-metallothionein injection model and that such toxicity can be prevented by pretreatment with CdCl2. The aim of the present study was to try to identify the subcellular targets of Cd nephrotoxicity by studying the binding of Cd to various proteins in subcellular fractions from the renal cortex of rats. By examining possible differences in such binding between animals with or without protective pretreatment, the importance of various targets for expression of toxicity could be indicated. Previously developed models for induction of nephrotoxicity and protective pretreatment (10, 12) were employed.
Materials and Methods

Animals
Male Wistar rats (200-250 g) from ALAB (Stockholm, Sweden) were used in this study. All animals were allowed to acclimatize for a minimum of 7 days prior to the experiment; they were maintained under controlled environmental conditions of temperature and humidity and with a 12-hr day-night cycle (2 A.M.-2 P.M.). Tap water and food (Ewos-ALAB rat-mouse food R3) were provided ad libitum. Four groups of rats, each consisting of two animals, were studied. Groups A and B were not pretreated with Cd but were subcutaneously injected with normal saline. The rats in groups C and D were given subcutaneous pretreatment injections with CdC12 in doses increasing in the following order: 0. 5, 1, 1, 2, 2 mg Cd/kg during 5 
Subcellular Fracdonation
The subcellular fractions were prepared ( Figure 1 ) by a differential centrifugation method described by Maunsbach (13) . The kidney cortex was dissected into small pieces and homogenized at 800 rpm and 100 strokes with a glass-Teflon homogenizer in cold 0.25 M sucrose and 0. 01 M Tris-HCl buffer in 0. 05 M NaCl, pH 7.5. The homogenate was centrifuged at 10OOg for 10 min. The pellets were rehomogenized and spun at 1iOOg for another 10 min. The resulting pellet was designated the nuclear fraction (1OOOg). The supernatants were combined and spun at 9500g for 10 min. The pellets were resuspended and spun at 9500g again. The resulting pellet was used as mitochondria fraction (9500g). The supernatants and lighter pellet portion were combined and spun at 29,700g for 10 min. The pellet obtained was designated the lysosome fraction (29,700g). The supernatants were spun at 47,000g for 20 min. This pellet was the plasma membrane (47,000g4). The supernatant was centrifuged at 105,000g for 60 min. Centrifugation was performed at 40C. The pellet was used as microsome fraction (105,OO0g) and the supernatant as the cytosol fraction. 109Cd content in the subcellular fractions was determined by Packard gamma scintillation system (Packard Instrument Co.) as described by Nordberg and Nishiyama (14) .
Chemicals
Tris-(hydroxymethyl)-aminomethan was from Merck (Germany). 109Cd was purchased from Amersham (UK). DOC (Deoxycholic acid sodium salts) was from Fulka Biochemicka (Switzerland). 109CdMT was prepared from rat liver as described by Nordberg et al. (15) . The metallothionein used in the present study had a Cd/Zn ratio of 37.0/13.5 and a E250/E280 ratio of 3.92.
Preparation ofSubcellular Protein Complexes
The subcellular fractions were Table 1 . Renalcortical Cd concentrations are similar to those previously reported at 24 hr after CdMT injection (10) and no obvious differences among groups related to pretreatment can be seen in total cortical Cd concentrations. There is a tendency towards a displacement of Cd from other fractions into the cytosol in the pretreated animals, but the proportions recovered in "membrane" and "microsome" fractions are not much different between pretreated and nonpretreated animals.
The results of gel filtration of subcellular fractions are shown in Figure 2 and Table 2 . Whereas the distribution of 109Cd was similar at 1 hr after the injection in nonpretreated and pretreated animals (groups A and C) there was a clear difference at 4 hr (groups B and D). In the nonpretreated animals (group B), most of the radioactivity appeared in high molecular weight (HMW) fractions, while, in the pretreated animals (group D), a major proportion of '09Cd appeared in two low molecular weight peaks, possibly corresponding to metallothionein in monomeric and dimeric form. This is shown also in Table  2 where the fractional distribution of total l19Cd in the various subcellular fractions is given. When considering the proportion of total membrane or microsome 1 Cd that is found in the HMW-fraction, there is no important difference between pretreated and nonpretreated animals at 1 hr, but a marked difference with 88% ("membrane") and 87% ("microsome") The observations in the present study provide new insights into these mechanisms, both the one behind expression of toxicity and the protective mechanism. The findings are in agreement with a hypothesis implying that sensitive targets of importance for development of Cd nephrotoxicity are present in the HMW part of the membrane and microsome fractions of renal 
